BriaCell Therapeutics Corp. (BCTX) Key Metrics
BCTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $29.6M
- Enterprise value
- $12.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.51
BCTX key metrics, FY2016–FY2025
Fiscal year ended July 31, 2025 · U.S. dollarsBCTX returns How much profit the business earns on the capital it uses.
BCTX financial health Debt, liquidity and how easily interest is covered.
BCTX efficiency & capital use Working capital cycle and where the cash goes.
BCTX valuation history
BCTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BCTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BCTX cash returned to shareholders
BCTX price vs earnings per share
BCTX key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $14.0M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$10.5M | — | — | — | — | — | — | — | — | — |
| Price / book | 0.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −259.8% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −278.2% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.46 | $112.88 | $993.88 | $965.65 | $754.70 | $1,068.94 | $2,137.50 | $4,495.50 | — | $7,578.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$19.37 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$20.74 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$20.74 | — | — | — | — | — | — | — | — | — |
| Cash per share | $13.04 | — | — | — | — | — | — | — | — | — |
| Book value per share | $13.05 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $12.92 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.9M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −343.0% | — | — | −143.9% | −111.5% | — | — | −638.0% | −418.6% | −229.3% |
| Return on assets (ROA) | −192.5% | −21.6% | −59.7% | −54.1% | −47.3% | — | −426.3% | −275.8% | −260.3% | −211.3% |
| Return on tangible assets | −123.7% | −60.9% | −75.3% | −63.4% | −23.9% | — | — | −269.0% | −196.6% | −267.0% |
| Financial health | ||||||||||
| Total debt | — | — | — | — | $32,476 | $249,799 | $322,526 | $1.1M | — | — |
| Cash & short-term investments | $24.6M | $1.2M | $28.4M | $52.6M | $71.6M | $21,249 | $157,034 | $1.7M | $1.6M | $820,597 |
| Net debt | −$24.6M | −$1.2M | −$28.4M | −$52.6M | −$71.5M | $228,550 | $165,492 | −$628,854 | −$1.6M | −$820,597 |
| Debt / equity | — | — | — | — | 0.00 | — | — | 1.19 | — | — |
| Debt / assets | — | — | — | — | 0.00 | 0.48 | 0.73 | 0.49 | — | — |
| Current ratio | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 | 1.40 | 1.84 | 17.15 |
| Quick ratio | 5.01 | 0.62 | 12.60 | 45.02 | 103.06 | 0.02 | 0.14 | 1.40 | 1.84 | 17.15 |
| Interest coverage | -735.7 | — | — | — | -87.0 | -145.7 | -198.7 | -244.4 | -623.4 | -604.8 |
| Working capital | $21.9M | −$5.3M | $33.6M | $53.1M | $71.5M | −$3.7M | −$964,788 | $537,519 | $748,327 | $784,754 |
| Invested capital | $20,018 | −$4.5M | −$33.4M | −$39.4M | −$37.0M | −$3.4M | −$523,173 | $316,162 | −$866,030 | −$33,492 |
| Tangible asset value | $23.6M | −$4.0M | −$5.3M | $13.0M | $34.3M | −$3.9M | −$964,786 | $670,283 | $750,231 | $787,104 |
| Net current asset value | $21.5M | −$6.8M | −$5.3M | $13.0M | $34.3M | −$3.9M | −$964,788 | $537,519 | $748,327 | $784,754 |
| Graham net-net per share | $10.20 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | $0 | $63,518 | $12.9M | $0 | — | — | — | — | — |
| Capex / depreciation | 0.00 | 7.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | 9,506.9 | 66,363.8 | 5,932.6 | 8,378.4 | 2,017.7 | 78.5 | — | 0.8 | 0.0 |
| Days payables outstanding | 17,855.9 | 25,318.3 | 24,620.0 | 10,388.2 | 3,184.3 | 51.8 | 2,696.2 | 7,775.2 | 556,697.1 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.02 | 0.01 | 0.01 | 0.04 | 0.11 | 7.05 | 0.14 | 0.05 | 0.00 | — |
| Inventory turnover | — | — | 0.01 | — | 0.04 | 0.18 | 4.65 | — | 459.86 | 8,585.71 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.3M | $1.4M | $494,736 | $23,312 | $19,114 | $12,666 | $8,690 | $10,082 | $4,135 | $14,916 |
| Average payables | $7.2M | $5.7M | $1.0M | $430,870 | $135,920 | $2,659 | $139,118 | $359,514 | $441,865 | — |
| Average inventory | — | $2.2M | $2.8M | $246,064 | $357,630 | $103,564 | $4,049 | $0 | $1 | $0 |
| Intangibles / total assets | 0.9% | 3.4% | 0.8% | 0.5% | 0.4% | 49.9% | 62.1% | 12.0% | 0.0% | 0.0% |
Computed from BCTX's annual financial statements (latest annual report filed October 16, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BCTX valuation and financial ratios
BriaCell Therapeutics earned a return on equity of −343.0% in fiscal 2025.
See the BCTX income statement, the BCTX chart for price history, or the BCTX stock overview for the latest quote and news.
BCTX key metrics FAQ
What is BriaCell Therapeutics's return on equity?
BriaCell Therapeutics's return on equity (ROE) was −343.0% in fiscal 2025: net income of -$36.5 million on average shareholders' equity of $10.6 million.
What is BriaCell Therapeutics's free cash flow yield?
BriaCell Therapeutics generated -$39.1 million of free cash flow in fiscal 2025, a free cash flow yield of −278.2% on its market value at year-end ($14.0 million).
What is BriaCell Therapeutics's current ratio?
BriaCell Therapeutics's current ratio was 5.01 at the end of fiscal 2025: current assets were 5.01 times current liabilities.